文献速递肾小球疾病遗传性与小管间质肾病

遗传性TRPC6足细胞病的基因型-表型相关性与临床结局

Genotype-phenotype correlations and clinical outcomes of genetic TRPC6 podocytopathies.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

这项多中心观察性研究通过在线问卷和系统文献综述,纳入87个家系(96例家族性、45例散发性)的TRPC6相关足细胞病患者,鉴定出31种错义变异。结果显示48.9%患者进展至肾衰竭,散发病例较家族性更早进展且更易表现为肾病综合征,p.R175W和p.R895C变异与更早进展至肾衰竭相关。

要点

  • 蛋白尿性肾病/肾病综合征是最常见临床表现(83.7%),局灶节段性肾小球硬化是最常见病理表现(89.4%)。
  • 散发性TRPC6相关足细胞病较家族性更早进展至肾衰竭(P=.001),且更易表现为肾病综合征(OR 4.34,95%CI 1.85-10.15;P=.001)。
  • p.R175W变异中位肾脏生存21年(HR 2.985,95%CI 1.40-5.79),p.R895C变异中位肾脏生存38年(HR 1.65,95%CI 1.01-2.81),log-rank P=.005。

核心结论

  • 本研究揭示了TRPC6相关足细胞病独特的临床与遗传相关性,可能有助于实现个体化诊疗和开发有前景的新疗法。

研究设计与样本

  • 多中心观察性研究,通过在线问卷结合系统文献综述建立队列,纳入87个家系(96例家族性病例和45例散发病例),共鉴定31种不同的TRPC6错义变异(包括2种新变异)。

主要发现

  • 蛋白尿性肾病/肾病综合征是最常见临床表现(83.7%),局灶节段性肾小球硬化是最常见组织学表现(89.4%)。
  • 至33(四分位距17-40)年时,48.9%(69/141)的患者已进展至肾衰竭。
  • 散发性TRPC6相关足细胞病较家族性病例更早进展至肾衰竭(P=.001),且更可能表现为肾病综合征(OR 4.34,95%CI 1.85-10.15;P=.001)。
  • 功能获得性TRPC6变异在家族性病例中较散发病例更常见(70.8% vs 44.4%;P=.004)。
  • 与携带其他TRPC6变异的患者相比,携带p.R175W变异者进展至肾衰竭更早(中位肾脏生存21年,HR 2.985,95%CI 1.40-5.79),携带p.R895C变异者亦更早(中位肾脏生存38年,HR 1.65,95%CI 1.01-2.81),log-rank P=.005。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: Podocytopathy associated with likely pathogenic/pathogenic variants of Transient receptor potential cation channel subfamily C member 6 (TRPC6) (TRPC6-AP) has been recognized for about 20 years. As a result of its rarity however, the spectrum of clinical phenotypes and genotype-phenotype correlation of TRPC6-AP remains poorly understood. Here, we characterized clinical, histological and genetic correlates of familial and sporadic patients with TRPC6-AP. METHODS: In this multicentre observational study, an online questionnaire followed by a systematic literature review was performed to create a cohort with comprehensive data on genetic and clinical outcomes [age of onset, clinical presentation, treatment response, kidney biopsy findings and progression to kidney failure (KF)]. Logistic regression, Cox proportional hazards model and Kaplan-Meier analyses investigated the associations between genetic variants and disease progression. RESULTS: Among 87 families (96 familial and 45 sporadic cases), 31 distinct missense TRPC6 variants (including 2 novel) were identified, with c.2683C>T p.(Arg895Cys) and c.523C>T p.(Arg175Trp) the commonest variants. Proteinuric kidney disease/nephrotic syndrome was the most common clinical presentation (83.7%), while focal segmental glomerulosclerosis was the most common histological finding (89.4%). By 33 (interquartile range 17-40) years, 48.9% (69/141) of patients had progressed to KF. Sporadic TRPC6-AP demonstrated an earlier progression to KF than familial cases (P = .001) and were more likely to present with nephrotic syndrome [odds ratio 4.34 (1.85-10.15); P = .001]. Gain-of-function TRPC6 variants were more frequent in familial than sporadic TRPC6-AP (70.8% vs 44.4%; P = .004). Compared with patients with other TRPC6 variants, patients with TRPC6 p.R175W and p.R895C variants progressed to KF earlier [median kidney survival of 21 years, hazard ratio 2.985 (95% confidence interval 1.40-5.79); and 38 years, hazard ratio 1.65 (95% confidence interval 1.01-2.81), respectively, log-rank P = .005]. CONCLUSION: Our study shows unique clinical and genetic correlations of TRPC6-AP, which may enable personalized care and promising novel therapies.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. McAnallen SM, Elhassan EAE, Stoneman S, et al. Genotype-phenotype correlations and clinical outcomes of genetic TRPC6 podocytopathies. Nephrol Dial Transplant. 2025. PMID: 40388293. doi:10.1093/ndt/gfaf086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。